Technor Inc.: Is This Shining Star Rising Or Falling?

LIVERMORE, CALIF.—It seemed like a great idea at the time: In the spring of 1987, chemist Bob Peny, armed with a quiet resolve and the patent to a pollution-reducing process he had discovered while a researcher at Sandia National Laboratory’s Combustion Research Facility (CRF) in Livermore, left a secure, challenging, and well-paying job to start his own company, Technor Inc. Launched with a Department of Energy Small Business and Innovation Research grant, the startup seemed de

Written byBruce Fellman
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

LIVERMORE, CALIF.—It seemed like a great idea at the time: In the spring of 1987, chemist Bob Peny, armed with a quiet resolve and the patent to a pollution-reducing process he had discovered while a researcher at Sandia National Laboratory’s Combustion Research Facility (CRF) in Livermore, left a secure, challenging, and well-paying job to start his own company, Technor Inc.

Launched with a Department of Energy Small Business and Innovation Research grant, the startup seemed destined to be a shining star in the federal government’s technology transfer heavens. Even the Secretary of Energy publicly acclaimed the “exciting potential” of Perry’s new technology. What better weapons could an enterprising scientist hope to be armed with upon sallying forth into the venture capital jungle?

So far, however, Bob Perry’s weapons haven’t been enough. His promising technology has yet to help anyone breathe easier—or to make him a millionaire. It will be at ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies